当前位置: 首页 > 期刊 > 《上海医药》 > 202021
编号:13826048
奥马珠单抗治疗儿童重度过敏性哮喘的快速卫生技术评估(4)
http://www.100md.com 2020年7月25日 《上海医药》 202021
     [10] Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children [J/OL]. Cochrane Database Syst Rev, 2014(1): CD003559 [2020-01-17]. doi: 10.1002/14651858.CD003559.pub4.

    [11] Corren J, Kavati A, Ortiz B, et al. Efficacy and safety of omalizumab in children and adolescents with moderate-tosevere asthma: a systematic literature review [J]. Allergy Asthma Proc, 2017, 38(4): 250-263.

    [12] Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents [J]. Pediatr Allergy Immunol, 2015, 26(6): 551-556.

    [13] Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis [J]. Value Health, 2014, 17(8): 772-782.

    [14] Zhou H, Lu Y, Wu B, et al. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children [J]. J Asthma, 2020, 57(1): 87-94.

    [15] 劉世英, 殷勇. 奥马珠单抗在儿童重度过敏性哮喘治疗中的应用[J]. 医学综述, 2019, 25(13): 2525-2529.

    [16] 陈宁, 贺建新, 卢根, 等. 奥马珠单抗治疗儿童过敏性哮喘的临床实践指南[J]. 国际儿科学杂志, 2019, 46(11): 773-781., 百拇医药(周华 车大钿)
上一页1 2 3 4